化橘红配方颗粒通过维持铁稳态并抑制脂质过氧化和铁死亡缓解斑马鱼脂肪性肝病

doi:10.12122/j.issn.1673-4254.2024.12.01

南方医科大学学报 ›› 2024, Vol. 44 ›› Issue (12): 2265-2275.doi: 10.12122/j.issn.1673-4254.2024.12.01

• • 下一篇

化橘红配方颗粒通过维持铁稳态并抑制脂质过氧化和铁死亡缓解斑马鱼脂肪性肝病

张榆雪¹(), 蓝洁莹¹, 马昕怡², 周琼¹, 秦梦晨¹, 高磊¹^,³^,⁴()

^1.南方医科大学，中医药学院，广东广州 510515
^2.南方医科大学，第一临床医学院，广东广州 510515
^3.广东省中药制剂重点实验室，广东广州 510515
^4.广东省中西医结合防治情志病基础研究卓越中心，广东广州 510515

收稿日期:2024-08-21 出版日期:2024-12-20 发布日期:2024-12-26
通讯作者: 高磊 E-mail:1610045163@qq.com;rayg@foxmail.com
作者简介:张榆雪，在读硕士研究生，E-mail: 1610045163@qq.com
基金资助:
国家自然科学基金(82074131);广东省基础与应用基础研究基金(2022A1515220179)

Exocarpium Citri Grandis formula granules alleviate fatty liver disease in Zebrafish by maintaining iron homeostasis and suppressing lipid peroxidation and ferroptosis

Yuxue ZAHNG¹(), Jieying LAN¹, Xinyi MA², Qiong ZHOU¹, Mengchen QIN¹, Lei GAO¹^,³^,⁴()

^1.School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China
^2.the First Clinical School of Medicine, Southern Medical University, Guangzhou 510515, China
^3.GuangDongProvicial Key Laboratory of Chinese Medicine Pharmaceutics, Guangzhou 510515, China
^4.Guangdong Province Integrated Traditional Chinese and Western Medicine Prevention and Treatment of emotional disease basic research excellence center, Guangzhou 510515

Received:2024-08-21 Online:2024-12-20 Published:2024-12-26
Contact: Lei GAO E-mail:1610045163@qq.com;rayg@foxmail.com
Supported by:
National Natural Science Foundation of China(82074131)

摘要/Abstract

摘要：

目的探讨化橘红配方颗粒治疗脂肪性肝病（FLD）的药效作用和具体机制。方法将受精后3 d的斑马鱼幼鱼随机分为空白组、模型对照组、化橘红配方颗粒处理组（16、32、64 μg/mL），分别构建斑马鱼幼鱼非酒精性脂肪肝（NAFLD）和酒精性脂肪肝（ALD）模型，采用生存分析、病理组织切片、全鱼油红O染色和实时定量荧光PCR实验评价化橘红配方颗粒治疗FLD的药效，并从CAV1和铁代谢及铁死亡角度探讨其治疗FLD的具体机制，通过普鲁士蓝染色、DCFH-DA活体探针、丙二醛含量检测、实时定量荧光PCR实验和CAV1免疫组织化学染色分析化橘红配方颗粒治疗FLD的药效验证和具体机制。结果化橘红配方颗粒能减轻斑马鱼幼鱼NAFLD和ALD模型中的脂质累积，减少脂肪酸合成酶、固醇调节元件结合蛋白1、3-羟基-3-甲基戊二酰辅酶A还原酶、肿瘤坏死因子-α和白介素6的表达水平，升高载脂蛋白A1和PPARα表达水平。化橘红配方颗粒可以减少斑马鱼幼鱼NAFLD和ALD模型中肝脏的铁沉积，减少幼鱼体内的丙二醛和活性氧含量（P<0.05）。NAFLD状态下，不同浓度的化橘红配方颗粒可升高Tf、TfR、FPN和SLC7A11表达（P<0.05），中、高浓度的化橘红配方颗粒可升高谷胱甘肽过氧化物酶4（GPX4）的表达（P<0.05）；ALD状态下，斑马鱼幼鱼的Tf、TfR和FPN表达升高，不同浓度的化橘红配方颗粒可降低这些基因的表达（P<0.05）。化橘红配方颗粒对ALD状态下SLC7A11的表达无明显影响，但高浓度的化橘红配方颗粒可升高GPX4的表达（P<0.05），免疫组织化学染色和实时定量荧光PCR实验结果显示，在NAFLD和ALD状态下，斑马鱼幼鱼肝脏的CAV1升高，而中、高浓度的化橘红配方颗粒可明显改善评价两种脂肪肝状态下斑马鱼幼鱼肝脏的CAV1表达。结论化橘红配方颗粒可减轻NAFLD和ALD的脂质累积和炎症反应，并通过减少CAV1的表达纠正NAFLD和ALD的铁稳态失衡、脂质过氧化和铁死亡。

关键词: 脂肪性肝病, 化橘红, 配方颗粒, 斑马鱼, 铁死亡

Abstract:

Objective To investigate the therapeutic effect of Exocarpium Citri Grandis formula granules (ECGFG) on fatty liver disease (FLD) in zebrafish and explore the underlying mechanism. Methods Nonalcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (ALD) models were established in zebrafish larvae at 3 days post fertilization (dpf), in which the treatment efficacy of 16, 32, or 64 μg/mL ECGFG was evaluated by examining zebrafish survival and liver pathologies and using whole-fish oil red O staining and RT-qPCR. The therapeutic mechanism of ECGFG for FLD was investigated using Prussian blue staining, DCFH-DA probe, MDA content detection, RT-qPCR assay and immunohistochemical staining for CAV1. Results In zebrafish models of NAFLD and ALD, treatment with ECGFG significantly reduced lipid accumulation and the expression levels of FASN, SREBP1, HMGCRA, TNF-α and IL-6, increased the expressions of Apoa1 and PPARα, and reduced iron deposition and the contents of MDA and ROS in the liver. In zebrafish models of NAFLD, treatment with ECGFG at the 3 doses significantly increased hepatic expressions of Tf, TfR, FPN and SLC7A11, and at the doses of 32 and 64 μg/mL, ECGFG obviously increased hepatic expression of GPX4. ALD fish models showed significantly increased hepatic expressions of Tf, TfR and FPN, which were effectively lowered by treatment with ECGFG at the 3 doses. ECGFG did not obviously affect the expression of SLC7A11, but its high dose (64 μg/mL) caused significant elevation of GPX4 expression. Both zebrafish models of NAFLD and ALD showed obviously increased CAV1 expression level in the liver, which was significantly reduced by treatment with 32 and 64 μg/mL ECGFG. Conclusion In zebrafish models of NAFLD and ALD, ECGFG can alleviate lipid accumulation and inflammatory response and lower the expression level of CAV1 to restore iron homeostasis and suppress lipid peroxidation and ferroptosis in the liver.

Key words: fatty liver disease, Exocarpium Citri Grandis, formula granules, zebrafish, iron homeostasis

张榆雪, 蓝洁莹, 马昕怡, 周琼, 秦梦晨, 高磊. 化橘红配方颗粒通过维持铁稳态并抑制脂质过氧化和铁死亡缓解斑马鱼脂肪性肝病[J]. 南方医科大学学报, 2024, 44(12): 2265-2275.

Yuxue ZAHNG, Jieying LAN, Xinyi MA, Qiong ZHOU, Mengchen QIN, Lei GAO. Exocarpium Citri Grandis formula granules alleviate fatty liver disease in Zebrafish by maintaining iron homeostasis and suppressing lipid peroxidation and ferroptosis[J]. Journal of Southern Medical University, 2024, 44(12): 2265-2275.

图/表 7

表1 引物序列

Tab.1 Primer sequences for RT-qPCR

Primer	Primer sequence (5'-3')	Primer sequence (5'-3')
β-actin	ATGGATGAGGAAATCGCTGCC	CTCCCTGATGTCTGGGTCGTC
FASN	GAGAAAGCTTGCCAAACAGG	GAGGGTCTTGCAGGAGACAG
SREBP1	CATCCACATGGCTCTGAGTG	CTCATCCACAAAGAAGCGGT
HMGCRA	CCTGTTAGCCGTCAGTGGA	TCTTTGACCACTCGTGCCG
PPARα	TGCTGGACTACCAGAACTGTGACA	TGCTGGCTGAGAACACTTCTGAG
Apoa1	GCACTAAGCTGACCGAGCGT	GGAGGTCCTGGGTGTGTGGA
TNF-α	GCTTATGAGCCATGCAGTGA	TGCCCAGTCTGTCTCCTTCT
IL6	CCTCAAACCTTCAGACCGCT	GAACAGGATCGAGTGGACCG
Tf	GTTGATGGTGGCCAGGTGTA	AGCGTAGTAACTTGCGGTCC
TfR	CCGCTCATACTCGCGGTTTA	TGGTTCAGAACGACCTGTGG
FPN	GCCAACGTCACCGTTTTTGA	CGGTCAAGTCGAAGGACCAA
GPX4	GAGGTTTACGCATCCTGGCT	GGCTGATCCTTCAGCCACTT
SLC7A11	TGTGGGAATGTCACTGGTGG	ACGCCTCCAGAATGTACGTG

图1 化橘红配方颗粒的斑马鱼急性毒性实验结果

Fig.1 Results of acute toxicity test of Exocarpium Citri Grandis (ECG) in zebrafish larvae. A: Development of zebrafish larvae 96 h after ECG administration. B: Effects of ECG granules on survival of zebrafish. C: Effects of ECG granules on heart rate of zebrafish at 96 h after administration.

图2 化橘红配方颗粒治疗非酒精性脂肪肝的药效评价

Fig.2 Efficacy evaluation of ECG decoction tablets and ECG granules for treatment of NAFLD in zebrafish larvae. A: HE staining of the liver of zebrafish larvae in each group. B: Whole fish oil red O staining in different groups. C: Effects of ECG decoction tablets and ECG granules on lipid metabolism-related genes and inflammatory factors. ECGFG:Exocarpium Citri Grandis formula granules.*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

图3 化橘红配方颗粒治疗酒精性脂肪肝的药效评价

Fig.3 Efficacy evaluation of ECG decoction tablets and ECG granules for treatment of ALD in zebrafish larvae. A: HE staining of the liver of zebrafish larvae in each group. B: Whole fish oil red O staining in different groups. C: Effects of ECG decoction tablets and ECG granules on lipid metabolism-related genes and inflammatory factors. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

图4 化橘红配方颗粒对非酒精性脂肪肝铁代谢和铁死亡的作用评估

Fig.4 Effect of ECG granules on iron metabolism and ferroptosis in zebrafish larvae models of NAFLD. A: Prussian blue staining of the liver of zebrafish larvae in each group. B: DCFH-DA probe detection of zebrafish larvae in each group. C: Detection of MDA content in zebrafish larvae in each group. D: Effects of ECG granules on iron metabolism- and ferroptosis-related genes. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

图5 化橘红配方颗粒对酒精性脂肪肝铁代谢和铁死亡的作用评估

Fig.5 Effect of ECG granules on iron metabolism and ferroptosis in zebrafish larvae models of ALD. A: Prussian blue staining of the liver of zebrafish larvae in each group. B: DCFH-DA probe detection of zebrafish larvae in each group. C: Detection of MDA content in zebrafish larvae in each group. D: Effects of ECG granules on expressions of iron metabolism- and ferroptosis-related genes. ***P<0.001, ****P<0.0001.

图6 化橘红配方颗粒可能通过CAV1调控肝铁代谢和铁死亡

Fig.6 ECG granules regulate hepatic iron metabolism and ferroptosis possibly through CAV1 in zebrafish larvae. A: Liver CAV1 immunohistochemical staining in zebrafish larvae models of NAFLD. B: Effect of ECG granules on CAV1 expression in zebrafish larvae models of NAFLD. C: Liver CAV1 immunohistochemical staining in zebrafish larvae models of ALD. D: Effect of ECG granules on CAV1 expression in zebrafish larvae models of ALD. ****P<0.0001.

参考文献 48

1	国家药典委员会. 中华人民共和国药典-一部: 2020年版[M]. 北京: 中国医药科技出版社, 2020.
2	范会云, 邓乔华, 宋松泉. “一片值千金”: 化橘红[J]. 生命世界, 2020(9): 40-1.
3	Musso G, Bo S, Cassader M, et al. Impact of sterol regulatory element-binding factor-1c polymorphism on incidence of nonalcoholic fatty liver disease and on the severity of liver disease and of glucose and lipid dysmetabolism[J]. Am J Clin Nutr, 2013, 98(4): 895-906.
4	中华中医药学会脾胃病分会, 张莉, 季光, 等. 非酒精性脂肪性肝病中医诊疗专家共识(2023)[J]. 中国中西医结合消化杂志, 2024, 10(1): 1-7.
5	毕占阳, 杨柱, 郭斌, 等. 基于酒伤理论探讨酒精性肝病的中医治疗[J]. 云南中医中药杂志, 2022, 43(5): 16-9.
6	李锦坤, 金刚亮, 王艳慧, 等. 化橘红提取物的制备工艺优化及其降脂作用[J/OL]. 现代食品科技, 2024,06. 10.13982/j.mfst.1673-9078.2024.10.0892
7	吴道顺, 王梦晨, 张雪涟, 等. 化橘红水提物对酒精诱导的急性肝损伤保护作用[J]. 中国实验方剂学杂志, 2022, 28(19): 42-8.
8	Deng GH, Liu C, Zhao JM, et al. Exocarpium Citri Grandis alleviates the aggravation of NAFLD by mitigating lipid accumulation and iron metabolism disorders[J]. J Ethnopharmacol, 2023, 313: 116559.
9	吴雄志, 卞兆祥, 陈新宇, 等. 中药配方颗粒临床应用国际专家共识[J]. TMR经典中医研究, 2021, 7(1): 19-26.
10	谭婉清, 王术玲, 刘潇潇, 等. 化橘红配方颗粒与饮片汤剂的化学等量性和药效等效性研究[J]. 中药新药与临床药理, 2023, 34(4): 541-9.
11	米永佳, 王茂泓, 李龙华, 等. 全国名中医张小萍教授治疗非酒精性脂肪肝经验[J]. 中国民族民间医药, 2024, 33(12): 80-3.
12	方俐晖, 郭志玲, 张轶斐, 等. 田德禄教授三期三脏辨治酒精性肝病经验[J]. 现代中医临床, 2021, 28(5): 38-42.
13	王艳慧. 化橘红的研究进展[J]. 世界科学技术-中医药现代化, 2017, 19(6): 1076-82.
14	苏志鹏. 化橘红活性成分的综合利用及对降血糖血脂活性的研究[D]. 广州: 广东药科大学, 2019.
15	吴祎. 化橘红解酒功效与保健食品的研究[D]. 广州: 广州中医药大学, 2014.
16	黄凯伟, 任应宗, 张辉, 等. 化橘红(柚)饮片、标准汤剂和配方颗粒相关性研究[J]. 中国药业, 2023, 32(17): 57-62.
17	Silva B, Faustino P. An overview of molecular basis of iron metabolism regulation and the associated pathologies[J]. Biochim Biophys Acta, 2015, 1852(7): 1347-59.
18	Vogt AC S, Arsiwala T, Mohsen M, et al. On iron metabolism and its regulation[J]. Int J Mol Sci, 2021, 22(9): 4591.
19	Graham RM, Chua AC, Herbison CE, et al. Liver iron transport[J]. World J Gastroenterol, 2007, 13(35): 4725-36.
20	Aigner E, Weiss G, Datz C. Dysregulation of iron and copper homeostasis in nonalcoholic fatty liver[J]. World J Hepatol, 2015, 7(2): 177-88.
21	Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression[J]. Cell Mol Life Sci, 2019, 76(1): 99-128.
22	Sun KX, Zhao JV, Nelson EAS, et al. Iron status and non-alcoholic fatty liver disease: a Mendelian randomization study[J]. Nutrition, 2024, 118: 112295.
23	Yu GF, Liu L, Qin T, et al. Associations of serum iron status with MAFLD and liver fibrosis in the USA: a nationwide cross-section study[J]. Biol Trace Elem Res, 2024, 202(1): 87-98.
24	Deng GH, Liu C, Zhao JM, et al. Exocarpium Citri Grandis alleviates
	the aggravation of NAFLD by mitigating lipid accumulation and iron
	metabolism disorders[J]. J Ethnopharmacol, 2023, 313: 116559.
25	Ali N, Ferrao K, Mehta KJ. Liver iron loading in alcohol-associated liver disease[J]. Am J Pathol, 2023, 193(10): 1427-39.
26	Li LX, Guo FF, Liu H, et al. Iron overload in alcoholic liver disease:
	mechanismsunderlying, effectsdetrimental, and therapeuticpotential
	targets[J]. Cell Mol Life Sci, 2022, 79(4): 201.
27	Chen JY, Li XP, Ge CD, et al. The multifaceted role of ferroptosis in liver disease[J]. Cell Death Differ, 2022, 29(3): 467-80.
28	Chen X, Li J, Kang R, et al. Ferroptosis: machinery and regulation[J]. Autophagy, 2021, 17(9): 2054-81.
29	Koppula P, Zhuang L, Gan BY. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy[J]. Protein Cell, 2021, 12(8): 599-620.
30	Xie YC, Kang R, Klionsky DJ, et al. GPX4 in cell death, autophagy, and disease[J]. Autophagy, 2023, 19(10): 2621-38.
31	Stockwell BR. Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications[J]. Cell, 2022, 185(14): 2401-21.
32	Chen X, Li JB, Kang R, et al. Ferroptosis: machinery and regulation[J]. Autophagy, 2021, 17(9): 2054-81.
33	Sui YT, Geng X, Wang ZW, et al. Targeting the regulation of iron homeostasis as a potential therapeutic strategy for nonalcoholic fatty liver disease[J]. Metabolism, 2024, 157: 155953.
34	Luo J, Song G, Chen NN, et al. Ferroptosis contributes to ethanol-induced hepatic cell death via labile iron accumulation and GPx4 inactivation[J]. Cell Death Discov, 2023, 9(1): 311.
35	Fernández-Rojo MA, Gongora M, Fitzsimmons RL, et al. Caveolin-1 is necessary for hepatic oxidative lipid metabolism: evidence for crosstalk between caveolin-1 and bile acid signaling[J]. Cell Rep, 2013, 4(2): 238-47.
36	Haddad D, Al Madhoun A, Nizam R, et al. Role of caveolin-1 in diabetes and its complications[J]. Oxid Med Cell Longev, 2020, 2020: 9761539.
37	Jiang Y, Krantz S, Qin X, et al. Caveolin-1 controls mitochondrial damage and ROS production by regulating fission - fusion dynamics and mitophagy[J]. Redox Biol, 2022, 52: 102304.
38	Fernández MA, Albor C, Ingelmo-Torres M, et al. Caveolin-1 is essential for liver regeneration[J]. Science, 2006, 313(5793): 1628-32.
39	Fernandez-Rojo MA, Ramm GA. Caveolin-1 function in liver physiology and disease[J]. Trends Mol Med, 2016, 22(10): 889-904.
40	Gao L, Zhou YC, Zhong WC, et al. Caveolin-1 is essential for protecting against binge drinking-induced liver damage through inhibiting reactive nitrogen species[J]. Hepatology, 2014, 60(2): 687-99.
41	Tao L, Wang JP, Wang K, et al. Exerkine FNDC5/irisin-enriched exosomes promote proliferation and inhibit ferroptosis of osteoblasts through interaction with Caveolin-1[J]. Aging Cell, 2024, 23(8): e14181.
42	Zhang T, Yang F, Dai XY, et al. Role of Caveolin-1 on the molybdenum and cadmium exposure induces pulmonary ferroptosis and fibrosis in the sheep[J]. Environ Pollut, 2023, 334: 122207.
43	Liu WH, Luo GH. CAV1 inhibits Xc (-) system through IFNGR1 to promote ferroptosis to inhibit stemness and improves anti-PD-1 efficacy in breast cancer[J]. Transl Oncol, 2024, 50: 102149.
44	Deng GH, Li YJ, Ma SY, et al. Caveolin-1 dictates ferroptosis in the execution of acute immune-mediated hepatic damage by attenuating nitrogen stress[J]. Free Radic Biol Med, 2020, 148: 151-61.
45	Huang S, Wang YH, Xie SW, et al. Isoliquiritigenin alleviates liver
	fibrosis through caveolin-1-mediated hepatic stellate cells ferroptosis
	in zebrafish and mice[J]. Phytomedicine, 2022, 101: 154117.
46	Amali AA, Rekha RD, Lin CJ, et al. Thioacetamide induced liver damage in zebrafish embryo as a disease model for steatohepatitis[J]. J Biomed Sci, 2006, 13(2): 225-32.
47	Tacke F. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis[J]. Expert Opin Investig Drugs, 2018, 27(3): 301-11.
48	Bautista AP. Neutrophilic infiltration in alcoholic hepatitis[J]. Alcohol, 2002, 27(1): 17-21.

[1]	陈鑫源, 吴成挺, 李瑞迪, 潘雪芹, 张耀丹, 陶俊宇, 林才志. 双术汤通过P53/SLC7A11/GPX4通路诱导胃癌细胞铁死亡[J]. 南方医科大学学报, 2025, 45(7): 1363-1371.
[2]	张梦影, 赵晨玲, 田丽伟, 余郭芳, 杨文明, 董婷. 肝豆扶木汤通过GPX4/ACSL4/ALOX15通路抑制铁死亡改善Wilson病小鼠的肝脏脂肪变性[J]. 南方医科大学学报, 2025, 45(7): 1471-1478.
[3]	郭卓琳, 张智恒, 郭新邓, 杨苇巍, 梁芷晴, 区锦莹, 曹惠慧, 卢子滨, 余林中, 刘俊珊. 银翘散配方颗粒与传统汤剂在抗炎、抗菌及镇痛药效的差异比较[J]. 南方医科大学学报, 2025, 45(5): 1003-1012.
[4]	张安邦, 孙秀颀, 庞博, 吴远华, 时靖宇, 张宁, 叶涛. 电针预处理通过调节肠道-大脑轴及Nrf2/HO-1信号通路抑制铁死亡减轻大鼠脑缺血再灌注损伤[J]. 南方医科大学学报, 2025, 45(5): 911-920.
[5]	张林落, 李长青, 皇玲玲, 周学平, 娄媛媛. 梓醇扶正制毒配伍从SLC7A11/GPX4通路抑制铁死亡减轻雷公藤甲素肝毒性[J]. 南方医科大学学报, 2025, 45(4): 810-818.
[6]	黄妍, 陈曦, 秦梦晨, 高磊. 活络效灵丹促进斑马鱼尾鳍再生的核心靶点与免疫调控机制[J]. 南方医科大学学报, 2025, 45(3): 494-505.
[7]	季春斐, 左宗超, 王钧, 李妙男. N-乙酰神经氨酸中通过抑制Nrf2轴促进缺氧/复氧损伤的H9C2心肌细胞发生铁死亡[J]. 南方医科大学学报, 2025, 45(1): 72-79.
[8]	陈凯, 孟兆菲, 闵静婷, 王佳慧, 李正红, 高琴, 胡俊锋. 姜黄素通过抑制TXNIP/TRX-1/GPX4通路介导的铁死亡减轻脓毒症小鼠肺损伤[J]. 南方医科大学学报, 2024, 44(9): 1805-1813.
[9]	欧阳明子, 崔佳琦, 王慧, 梁正, 皮大锦, 陈利国, 陈前军, 吴迎朝. 开心散通过减轻前额叶皮质铁死亡缓解小鼠的阿霉素化疗性抑郁[J]. 南方医科大学学报, 2024, 44(8): 1441-1449.
[10]	张银亮, 骆泽谭, 赵睿, 赵娜, 徐志东, 奥迪, 丛古一, 刘新宇, 郑海伦. 血根碱通过调控STUB1/GPX4诱导直肠癌细胞发生铁死亡[J]. 南方医科大学学报, 2024, 44(8): 1537-1544.
[11]	王元国, 张鹏. 铁死亡抑制基因在食管癌中的高表达分析[J]. 南方医科大学学报, 2024, 44(7): 1389-1396.
[12]	何华星, 刘璐琳, 刘颖茵, 陈纳川, 孙素霞. 丁酸钠与索拉非尼可能通过YAP诱导铁死亡协同抑制肝癌细胞增殖[J]. 南方医科大学学报, 2024, 44(7): 1425-1430.
[13]	任智先, 周倍贤, 王林鑫, 李菁, 张荣平, 潘锡平. 5-羟基-6，7-二甲氧基黄酮抑制流感病毒诱导A549细胞炎症反应和铁死亡的作用及机制[J]. 南方医科大学学报, 2024, 44(6): 1070-1078.
[14]	张方圆, 刘刚. 右美托咪定通过激活Nrf2/HO-1/GPX4通路抑制肾小管上皮细胞的铁死亡[J]. 南方医科大学学报, 2024, 44(6): 1135-1140.
[15]	王南, 石斌, 马小兰, 吴伟超, 曹佳. FMRP通过激活RAS/MAPK信号通路抑制结直肠肿瘤细胞的铁死亡[J]. 南方医科大学学报, 2024, 44(5): 885-893.

化橘红配方颗粒通过维持铁稳态并抑制脂质过氧化和铁死亡缓解斑马鱼脂肪性肝病

Exocarpium Citri Grandis formula granules alleviate fatty liver disease in Zebrafish by maintaining iron homeostasis and suppressing lipid peroxidation and ferroptosis

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 7

参考文献 48

相关文章 15

编辑推荐

Metrics

本文评价